Today, immunohistochemical markers are routinely used alone or in association to examine thyroid lesions but without sufficient sensitivity and specificity regarding to cancer diagnosis. Additional markers are currently identified among genetic alterations or miRNA panels carrying significant diagnostic values. Combining immunostaining data, mutation status, gene rearrangement and miRNA expression should help to define an integrative signature for the accurate diagnosis of thyroid carcinomas.